Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients
Evangelos D. Michelakis(University of Alberta), Martin R. Wilkins(Hammersmith Hospital), Stephen J. Wort(Imperial College London), Adam Kinnaird(University of Alberta), Geoffrey Watson(Imperial College London), J. Simon R. Gibbs(Imperial College London), Richard B. Thompson(University of Alberta), Christopher W. White(University of Alberta), Kelvin Chow(University of Alberta), Vikram Gurtu(University of Alberta), Gareth Barnes(Imperial College London), John Wharton(Pfizer (United Kingdom)), John Cupitt(Imperial College London), Declan P. O’Regan(MRC Clinical Trials Unit at UCL), D. Ian Paterson(University of Alberta), Aristeidis E. Boukouris(University of Crete), Jayan Nagendran(University of Alberta), Darren H. Freed(University of Alberta), Lan Zhao(Tianjin Fourth Central Hospital), Luke Howard(Imperial College London), Linda Webster(University of Alberta), David G. Kiely(Royal Hallamshire Hospital)
Cited by 311
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth
|Cancer Cell|2007|1.5k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k
Mechanisms of disease: pulmonary arterial hypertension
|Nature Reviews Cardiology|2011|784